| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,530,000 |
| Market
Cap: |
316.57(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.43 - $11.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,097 |
48,760 |
128,859 |
316,555 |
| Total Sell Value |
$219,422 |
$312,579 |
$590,703 |
$820,459 |
| Total People Sold |
2 |
3 |
3 |
3 |
| Total Sell Transactions |
2 |
5 |
12 |
34 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Liao Carrie |
VP, Controller&Acct Principal |
• – – |
2023-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
478,430 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2023-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
385,505 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2023-03-01 |
4 |
S |
$3.51 |
$12,555 |
D/D |
(3,577) |
260,505 |
|
-22% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2023-03-01 |
4 |
S |
$3.51 |
$29,038 |
D/D |
(8,273) |
238,959 |
|
-22% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-12-21 |
4 |
S |
$2.69 |
$10,386 |
D/D |
(3,861) |
247,232 |
|
-37% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-12-21 |
4 |
S |
$2.69 |
$3,258 |
D/D |
(1,211) |
264,082 |
|
-37% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-10-27 |
4 |
S |
$3.00 |
$1,932 |
D/D |
(644) |
265,293 |
|
-4% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-10-25 |
4 |
S |
$2.81 |
$1,520 |
D/D |
(541) |
265,937 |
|
-13% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-10-25 |
4 |
S |
$2.81 |
$3,392 |
D/D |
(1,207) |
251,093 |
|
-13% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-10-18 |
4 |
S |
$3.11 |
$3,794 |
D/D |
(1,220) |
252,300 |
|
-16% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-09-27 |
4 |
S |
$5.87 |
$3,757 |
D/D |
(640) |
266,478 |
|
34% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-09-26 |
4 |
S |
$5.51 |
$6,965 |
D/D |
(1,264) |
253,520 |
|
34% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-09-26 |
4 |
S |
$5.51 |
$3,113 |
D/D |
(565) |
267,118 |
|
34% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-09-16 |
4 |
S |
$7.26 |
$9,801 |
D/D |
(1,350) |
254,784 |
|
56% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-08-31 |
4 |
S |
$11.67 |
$14,331 |
D/D |
(1,228) |
256,134 |
|
73% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-08-31 |
4 |
S |
$11.67 |
$14,051 |
D/D |
(1,204) |
267,683 |
|
73% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-08-16 |
4 |
S |
$0.68 |
$13,838 |
D/D |
(20,350) |
3,860,438 |
|
- |
|
| Bruhn Suzanne Louise |
Director |
– • – |
2022-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
89,286 |
89,286 |
|
- |
|
| Crystal Roger |
Director |
– • – |
2022-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
89,286 |
89,286 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-07-27 |
4 |
S |
$0.69 |
$6,801 |
D/D |
(9,856) |
4,033,264 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-07-25 |
4 |
S |
$0.69 |
$5,769 |
D/D |
(8,361) |
4,043,120 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-07-25 |
4 |
S |
$0.69 |
$12,890 |
D/D |
(18,681) |
3,880,788 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-07-18 |
4 |
S |
$0.70 |
$13,572 |
D/D |
(19,388) |
3,899,469 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-06-27 |
4 |
S |
$0.70 |
$18,367 |
D/D |
(26,238) |
4,051,481 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-06-27 |
4 |
S |
$0.70 |
$25,733 |
D/D |
(36,762) |
3,918,857 |
|
- |
|
79 Records found
|
|
Page 2 of 4 |
|
|
0.56 (6.64%) 
